Based on the BRF113928 study, the US Food and Drug Administration (FDA) approved the indication for the combination of dabrafenib (BRAF inhibitor) + trametinib (MEK inhibitor) for the treatment of advanced NSCLC patients carrying the BRAF V600E mutation in December 2017 (Odogwu et al. 2018). Here, MAP2K7 is linked to non-small cell lung carcinoma.